MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: spasticity"

  • 2024 International Congress

    Social Media Listening Study to Understand the Journey and Unmet Needs of Patients Living With PSS

    S. Carda, J. Wissel, D. Hoad, G. Francisco, M. Verduzco-Gutierrez, D. Gallardo, M. Vacchelli, J. Jacinto (Lausanne, Switzerland)

    Objective: To employ social media listening to uncover insights into poststroke spasticity (PSS) patient experiences, unmet needs, and impact on quality of life. Background: PSS…
  • 2023 International Congress

    Putting the patient’s voice at the venter: Tracking the impact of botulinum neurotoxin therapy for movement disorders using patient-reported outcomes

    S. Samadzadeh, V. Koska, J. Waskönig, PJ. Jouvenal, SGM. Meuth, HH. Hefter, PA. Albrecht (Düsseldorf, Germany)

    Objective: To investigate how patient reported outcomes (PROs) perform to document the effects of a botulinum neurotoxin (BONT) treatment of movement disorders in the clinical…
  • 2023 International Congress

    Quantitative gait analysis to evaluate changes in gait pattern after Botulinum toxin A injection by hemiparesis

    M. Pinter, M. Petrovicsova, Y. Teuschl, A. Dachenhausen, K. Matz, C. Bancher (Krems, Austria)

    Objective: This retrospective study aimed to assess the effect of Botulinum toxin A (BoNT-A) injections in the lower limbs of hemiparetic patients on gait parameters,…
  • 2022 International Congress

    Safety of incobotulinumtoxinA in pediatrics: A pooled analysis

    F. Heinen, M. Banach, E. Dabrowski, D. Gaebler-Spira, H. Chambers, S. Schroeder, T. Geister, M. Althaus, A. Hanschmann, S. Berweck (Munich, Germany)

    Objective: To present analyses of pooled data on the safety of incobotulinumtoxinA (INCO) in pediatrics Background: BotulinumtoxinA (BoNT-A) is used to treat several conditions affecting…
  • 2022 International Congress

    Pain and Disability Outcomes in Hemiparetic Patients Naive to Botulinum Toxins With Upper and Lower Limb Spasticity Treated With OnabotulinumtoxinA: Insights From the ASPIRE Study

    G. Bavikatte, A. Esquenazi, W. Jost, A. Barichich, E. Duarte, M. Schwartz, T. Musacchio, G. Francisco (Liverpool, United Kingdom)

    Objective: To assess measures of pain and functional impairment in patients treated with onabotulinumtoxinA (onabotA) who are naive to botulinum toxins with upper limb (UL)…
  • 2022 International Congress

    Pain reduction in adult patients with limb spasticity following a single incobotulinumtoxinA injection: an analysis of pooled data from phase 2 and 3 studies

    J. Wissel, A. Camões-Barbosa, G. Comes, M. Althaus, A. Scheschonka, D. Simpson (Potsdam, Germany)

    Objective: To assess pain relief in a large cohort of incoA-treated pts with spasticity-associated pain (SAP) using pooled data from mostly placebo-controlled phase 2/3 studies.…
  • 2022 International Congress

    Benefit of multiple incobotulinumtoxinA injections for pain reduction in adult patients with limb spasticity: an analysis of pooled data from phase 2 and 3 studies

    J. Wissel, A. Camões-Barbosa2, G. Comes, M. Althaus, A. Scheschonka, D. Simpson (Potsdam, Germany)

    Objective: To assess pain relief after multiple incoA injections in a large sample of pts with limb spasticity-associated pain (SAP) using pooled data from six…
  • 2022 International Congress

    Pooled safety analysis of incobotulinumtoxinA in the treatment of neurological disorders in adults

    C. Comella, M. Hast, A. Hanschmann (Chicago, USA)

    Objective: To examine the pooled incidence of treatment-emergent adverse events (TEAEs) and immunogenicity by indication in sponsored incobotulinumtoxinA (INCO) clinical trials in adults. Background: The…
  • 2022 International Congress

    Choice of shoulder muscles for the multi-pattern treatment of upper limb spasticity with botulinum neurotoxin injections

    J. Jacinto (Alcabideche, Portugal)

    Objective: To present an experts’ consensus on the use of botulinum neurotoxin (BoNT) injections in the multi-pattern treatment of shoulder spasticity to increase awareness of…
  • 2022 International Congress

    Lack of immunogenicity of incobotulinumtoxinA in pediatrics: A pooled analysis

    F. Heinen, M. Banach, E. Dabrowski, D. Gaebler-Spira, H. Chambers, S. Schroeder, T. Geister, M. Althaus, A. Hanschmann, S. Berweck (Munich, Germany)

    Objective: To present pooled data analyses of the immunogenicity of incobotulinumtoxinA (INCO) in pediatrics. Background: BotulinumtoxinA (BoNT-A) is used to treat several chronic pediatric conditions,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25111 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley